Hilton Santa Fe Historic Plaza Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2006



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Advances in the Understanding and Treatment of Melanoma (A6)


Organizer(s) Patrick Hwu, Elizabeth Grimm and James Mulé
January 18—23, 2006
Hilton Santa Fe Historic Plaza Hotel • Santa Fe, New Mexico USA
Abstract Deadline: Sep 19, 2005
Late Abstract Deadline: Oct 11, 2005
Scholarship Deadline: Sep 19, 2005
Early Registration Deadline: Nov 18, 2005

Supported by The Director's Fund

Summary of Meeting:
Because of its inherent immunogenicity and abundant vascularity, melanoma provides a unique opportunity to develop novel molecular, immunologic and anti-angiogenic therapies that can then be generalized to other diseases. Some consider melanoma the "E.coli" in which to develop new cancer therapies. Three of the most exciting areas in this field involve molecular targeting of specific pathways, cancer vaccines and immunotherapy, and anti-vascular therapies. However, none of these areas alone are likely to have significant impact in the disease, and the use of multiple approaches will be critical. While there are many meetings which focus on a particular treatment approach, this program will bring together a multidisciplinary group that will explore the interactions among these distinct therapeutic strategies. We envision that basic and clinical research in melanoma will lead the way in integrating molecular targeting, immunologic, and anti-vascular therapies and can serve as a model for the treatment of other diseases.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


WEDNESDAY, JANUARY 18

15:00—19:30
Registration

Promenade
18:30—19:30
Refreshments

Promenade
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
Richard M. Marais, Cancer Research UK Manchester Institute, UK
Mechanisms of RAF Signaling in Cancer


THURSDAY, JANUARY 19

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Epidemiology and Prevention of Melanoma
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
Margaret A. Tucker, National Cancer Institute, National Institutes of Health, USA
Who is at Risk of Melanoma?

* Marianne Berwick, University of New Mexico Health Sciences Center, USA
Gene-Environment Interactions in Melanoma

Qingyi Wei, University of Texas MD Anderson Cancer Center, USA
DNA Repair and Susceptibility to Melanoma

Christina K. Augustine, Duke University and VA Medical Centers, USA
Short talk: Optimizing Regional Melanoma Therapy Using Pharmacogenomic Strategies

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Ortiz
13:00—22:00
Poster Viewing

Ortiz
14:00—16:30
Workshop 1: Melanoma Immunotherapy

Mesa A-B
* Bernard A. Fox, Earle A Chiles Research Institute, USA
Exploiting Lymphopenia to Augment Vaccine Efficacy

* James J. Mulé, H. Lee Moffitt Cancer Center & Research Institute, USA

Daniel E. Speiser, Ludwig Center, University of Lausanne, Switzerland
Ex Vivo Detectable Human CD8 T-Cell Responses to CT Antigens in 4/4 Patients Vaccinated with Stable Peptide / IFA Emulsions

Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, USA
Clinical Development of DNA Vaccines for Melanoma

Christopher Austin Klebanoff, Memorial Sloan Kettering Cancer Center, USA
Removal of Homeostatic Cytokine Sinks by Lymphodepletion Enhances the Efficacy of Adoptively Transferred Tumor-Specific CD8+ T Cells

Karen Hastings, University of Arizona College of Medicine, Phoenix, USA
Lysosomal Thiol Reductase GILT is Essential for MHC Class II Processing of Melanocyte Differentiation Antigen TRP-1

16:30—17:00
Coffee Available

Promenade
17:00—19:00
Prognostic Markers for Melanoma Progression
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* James J. Mulé, H. Lee Moffitt Cancer Center & Research Institute, USA

David S.B. Hoon, John Wayne Cancer Institute, USA
Prognostic Markers for Melanoma Progression

David E. Elder, University of Pennsylvania School of Medicine, USA
Markers of Tumor Progression, Diagnosis and Prognosis in Melanoma

David Rimm, Yale University, USA
Quantitative Multiplexed Analysis of TMAs to Discover Prognostic Factors for Melanoma

19:00—20:00
Social Hour with Lite Bites

Ortiz/Chamisa
19:30—22:00
Poster Session 1

Ortiz/Chamisa

FRIDAY, JANUARY 20

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Molecular Biology of Melanoma I
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Meenhard Herlyn, Wistar Institute, USA
Targeting Signaling Pathways for Melanoma Therapy

Peter Hersey, University of Newcastle, Australia
TRAIL Biology and Melanoma

Ann Richmond, Vanderbilt University School of Medicine, USA
Targeting NF-kappaB and Autocrine Signaling Pathways in Melanoma

Bahija Jallal, MedImmune, Inc., USA
Targeted Therapeutics in Melanoma: Changing the Front End of Drug Development

Penny Emma Lovat, Newcastle University, UK
Short Talk: Fenretinide-Induced Apoptosis Via Endoplasmic Reticulum Stress- New Drug Targets for Melanoma Therapy?

09:20—09:40
Coffee Break

Promenade
14:00—16:30
Workshop 2: Staging and Biomarkers

Mesa A-B
* Vernon K. Sondak, H. Lee Moffitt Cancer Center & Research Institute, USA
The Need for New Biomarkers of Melanoma Nodal Metastasis

* Merrick I. Ross, University of Texas MD Anderson Cancer Center, USA
Future Approaches to Melanoma Staging

Steven Everett, Ninewells Hospital & Medical School, UK
Cytochrome P450 Cyp1b1 Expression in Primary and Metastatic Melanoma

Stergios Moschos, University of Pittsburgh Medical Center, USA
Ubc9, is the Most Highly Expressed Protein in Melanoma Infiltrated Lymph Nodes and its Downregulation, Alone or in Combination with Chemotherapy/Radiation, Increases Cell Death in Melanoma Cell Lines

Phyllis A. Gimotty, University of Pennsylvania, USA
Staging Thin (< 1.00mm) Invasive Cutaneous Melanomas

Rosalynn M. Nazarian, Massachusetts General Hospital, USA
Mitf, Bcl-2 and Inos Expression in Melanocytic Tumor Progression Using a Tissue Microarray Approach

Jeffrey E. Gershenwald, University of Texas MD Anderson Cancer Center, USA
Heterogeneity of Microscopic Stage III Melanoma in the SLN Era: Implications for AJCC/UICC Staging and Future Clinical Trial Design

16:30—17:00
Coffee Available

Promenade
17:00—19:00
Molecular Biology of Melanoma II
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
Frank Meyskens, University of California, Irvine, USA
The Pathogenesis of Human Melonoma is a Redox-Driven/Regulated Process: Etiologic, Preventitive and Therapeutic Implications

* Elizabeth A. Grimm, University of Texas MD Anderson Cancer Center, USA
Role of Endogenous Nitric Oxide in Melanoma

Somasekar Seshagiri, Genentech, Inc., USA
Short Talk: Oncogenic BRAF is Required for Tumor Growth and Maintenance in Melanoma Models

19:00—20:00
Social Hour with Lite Bites

Ortiz/Chamisa

SATURDAY, JANUARY 21

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Preclinical Studies of Melanoma Immunotherapy
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
Herbert B. Slade, DFB Pharmaceuticals, USA
Application of Toll-Like Receptor 7/8 Agonists in Cancer Therapy

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Melanoma-Associated Genetic Mutations Targeted by Human CD4+ T Cells

* Patrick Hwu, University of Texas MD Anderson Cancer Center, USA
Murine Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells and NK Cells in the Induction of Anti-Tumor Immune Responses In Vivo

Giorgio Parmiani, Fondazione Centro San Raffaele Del MonteTabor, Italy
New Immunosuppressive Mechanisms in Melanoma Patients

Thomas S. Kupper, Brigham and Women's Hospital, USA
Short Talk: Approaches to Optimizing Melanoma Immunotherapy

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Ortiz
13:00—22:00
Poster Viewing

Ortiz
14:00—16:30
Panel Discussion: Overcoming Barriers to Translational Research

Mesa A-B
* Lynn Schuchter, University of Pennsylvania, USA

* Walter J. Urba, Earle A. Chiles Research Institute, USA

Francesco M. Marincola, Sidra Medical and Research Center, Qatar
Title to be Determined

16:30—17:00
Coffee Available

Promenade
17:00—19:00
Melanoma Clinical Immunotherapy Trials
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Jeffrey Weber, New York University, USA
Phase II Trials of Class II Melanoma Peptides and Class I Peptides with IL-12 and Alum for Resected High Risk Melanoma

Thomas Gajewski, University of Chicago, USA
Gene Expression Profile of Melanoma Tumor Microenvironment Associated with Favorable Clinical Outcome to a Multipeptide Vaccine

A. Karolina Palucka, Tha Jackson Laboratory for Genomic Medicine, USA
Dendritic Cell Vaccines in Melanoma

F. Stephen Hodi, Dana-Farber Cancer Institute, USA
Short Talk: Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Antibody Blockade in Previously Vaccinated Melanoma and Ovarian Cancer Patients

19:00—20:00
Social Hour with Lite Bites

Ortiz/Chamisa
19:30—22:00
Poster Session 2

Ortiz/Chamisa

SUNDAY, JANUARY 22

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Antivascular Approaches for Melanoma
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Menashe Bar-Eli, University of Texas MD Anderson Cancer Center, USA
Gene Regulation in Melanoma Angiogenesis

Mary J.C. Hendrix, Children's Memorial Research Center at Northwestern University, USA
The Clinical Implications of Melanoma Tumor Cell Plasticity

Wen-Jen Hwu, University of Texas MD Anderson Cancer Center, USA
Treatment of Melanoma with Thalidomide and Its Analogues: Antivascular, and Immunomodulatory Activity

Steven K. Libutti, Albert Einstein College of Medicine, USA
Clinical Trials of Antivascular Agents in Melanoma

09:20—09:40
Coffee Break

Promenade
14:00—16:30
Workshop 3: Melanoma Signal Transduction and Targeted Therapies

Mesa A-B
* Frank G. Haluska, ARIAD Pharmaceuticals, Inc., USA

* Jeffrey E. Lee, University of Texas MD Anderson Cancer Center, USA

Staffan Stromblad, Karolinska Institutet, Sweden
Rescue of Integrin alphaV-Dependent Unfolding of Wild Type p53 Suppresses Melanoma Tumor Growth

Romina Marone, Institute of Biochemistry and Genetics, Switzerland
Targeting Melanoma – Which Phosphoinositide 3-Kinase Isoform?

Kevin B. Kim, University of Texas MD Anderson Cancer Center, USA
Changes in Expressions of Phosphorylated-AKT in Metastatic Melanoma Lesions after Imatinib Treatment

Alexander J.F. Lazar, University of Texas MD Anderson Cancer Center, USA
PTEN Expression, BRAF and NRAS Mutational Status in Primary Cutaneous Melanoma

16:30—17:00
Coffee Available

Promenade
17:00—17:45
Workshop 4: Epidemiology and Molecular Biology

Mesa A-B
* Thomas S. Kupper, Brigham and Women's Hospital, USA

Craig Ceol, Children's Hospital Boston, USA
Short Talk: Using the Zebrafish to Identify and Characterize Mutations that Cause Melanoma

Michael Ming, University of Pennsylvania, USA
Short Talk: Statins, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Calcium Channel bBockers (CCBs) are Prescribed Less Frequently for Patients who Later Develop Melanoma

Levi A. Garraway, Eli Lilly and Company, USA
Short Talk: Linking Genetic Dependency to Therapeutic Vulnerability in Melanoma

17:45—18:45
Concluding Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center, USA
The Future of Melanoma Therapy

18:45—19:00
Announcement of Poster Contest Winners
Meeting has ended...abstracts no longer viewable online.

* Patrick Hwu, University of Texas MD Anderson Cancer Center, USA

19:00—20:00
Social Hour with Lite Bites

Mesa C
20:00—23:00
Entertainment

Mesa C

MONDAY, JANUARY 23

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA117400-01




We gratefully acknowledge additional support for this conference from:

Melanoma Research Foundation Novartis Institutes for BioMedical Research
Schering-Plough Corporation
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



3M Pharmaceuticals


Chiron Corporation


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676